CN107811669A - The method of fluid intervention is carried out for the microtubular of ganglioside GM_3 operation and using it - Google Patents
The method of fluid intervention is carried out for the microtubular of ganglioside GM_3 operation and using it Download PDFInfo
- Publication number
- CN107811669A CN107811669A CN201711197379.XA CN201711197379A CN107811669A CN 107811669 A CN107811669 A CN 107811669A CN 201711197379 A CN201711197379 A CN 201711197379A CN 107811669 A CN107811669 A CN 107811669A
- Authority
- CN
- China
- Prior art keywords
- microtubular
- suppository
- developer liquids
- solution
- peripheral channel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 30
- PFJKOHUKELZMLE-VEUXDRLPSA-N ganglioside GM3 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@@H]([C@H](O)/C=C/CCCCCCCCCCCCC)NC(=O)CCCCCCCCCCCCC\C=C/CCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 PFJKOHUKELZMLE-VEUXDRLPSA-N 0.000 title claims abstract description 5
- 239000012530 fluid Substances 0.000 title claims description 21
- 239000007788 liquid Substances 0.000 claims abstract description 43
- 229920000642 polymer Polymers 0.000 claims abstract description 24
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 17
- 239000000829 suppository Substances 0.000 claims abstract description 14
- 239000007864 aqueous solution Substances 0.000 claims abstract description 10
- 230000002093 peripheral effect Effects 0.000 claims abstract description 8
- 238000007711 solidification Methods 0.000 claims abstract description 5
- 230000008023 solidification Effects 0.000 claims abstract description 5
- 235000007164 Oryza sativa Nutrition 0.000 claims abstract description 4
- 235000012149 noodles Nutrition 0.000 claims abstract description 4
- 235000009566 rice Nutrition 0.000 claims abstract description 4
- 240000007594 Oryza sativa Species 0.000 claims abstract 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 48
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 claims description 15
- UFRKOOWSQGXVKV-UHFFFAOYSA-N ethene;ethenol Chemical compound C=C.OC=C UFRKOOWSQGXVKV-UHFFFAOYSA-N 0.000 claims description 15
- 239000004715 ethylene vinyl alcohol Substances 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 7
- 229910000510 noble metal Inorganic materials 0.000 claims description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 238000013461 design Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000004698 Polyethylene Substances 0.000 claims description 3
- 238000011161 development Methods 0.000 claims description 3
- 229920000573 polyethylene Polymers 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 230000033228 biological regulation Effects 0.000 claims description 2
- -1 polyethylene Polymers 0.000 claims description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical group CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims 4
- 239000012046 mixed solvent Substances 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 229910001080 W alloy Inorganic materials 0.000 claims 1
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 1
- ZONODCCBXBRQEZ-UHFFFAOYSA-N platinum tungsten Chemical compound [W].[Pt] ZONODCCBXBRQEZ-UHFFFAOYSA-N 0.000 claims 1
- 150000004040 pyrrolidinones Chemical class 0.000 claims 1
- 238000005516 engineering process Methods 0.000 abstract description 14
- 201000008450 Intracranial aneurysm Diseases 0.000 abstract description 7
- 239000012071 phase Substances 0.000 description 20
- 206010002329 Aneurysm Diseases 0.000 description 12
- 239000000835 fiber Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 208000005189 Embolism Diseases 0.000 description 8
- 210000001367 artery Anatomy 0.000 description 7
- 210000003462 vein Anatomy 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 3
- 230000003073 embolic effect Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 241000209094 Oryza Species 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229920001038 ethylene copolymer Polymers 0.000 description 2
- 201000011066 hemangioma Diseases 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010008088 Cerebral artery embolism Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 229920001410 Microfiber Polymers 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 239000011806 microball Substances 0.000 description 1
- 238000004377 microelectronic Methods 0.000 description 1
- 239000003658 microfiber Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000003294 onyx copolymer Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229910052715 tantalum Inorganic materials 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 201000009371 venous hemangioma Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12099—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder
- A61B17/12109—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder in a blood vessel
- A61B17/12113—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder in a blood vessel within an aneurysm
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
- A61B17/12181—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/02—Surgical adhesives or cements; Adhesives for colostomy devices containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/06—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
- A61B2090/3966—Radiopaque markers visible in an X-ray image
Landscapes
- Health & Medical Sciences (AREA)
- Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Pathology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Inorganic Chemistry (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials Engineering (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a kind of microtubular for ganglioside GM_3 operation, the microtubular comprises at least the central passage being coaxially disposed and peripheral channel, central passage is can developer liquids suppository path, peripheral channel is the aqueous solution channel for having viscosity, can spiralization and solidification of the developer liquids suppository in microtubular with realization.Microflow control technique, liquid embolizing agent technology and microtubular technology are combined by the technology, and the technology can realize that liquid embolizing agent in solidifying in microtubular, forms the filling " polymer springs circle " developed of spiral rice noodles shape.The polymer " turn " can be applied to intracranial aneurysm filling operation.
Description
Technical field
The present invention relates to ganglioside GM_3 field of surgical, more specifically to one kind by microflow control technique, liquid bolt
The new technology that suppository technology and microtubular technology are combined, the technology can realize liquid embolizing agent in solidifying in microtubular, shape
Into the filling " polymer springs circle " developed of spiral rice noodles shape.
Background technology
Due to mechanical damage, vascular sclerosis, hypertension, the hyperplasia of vascular smooth muscle cells, bacterium or virus infection, vein
The effect of the internal and external factor such as the induction of valve disease or blood flow impact, can form hemangioma in artery and vein vascular.Hemangioma is divided into
Aneurysm and phlebangioma, wherein, the aneurysm with boss wall in encephalic is produced, referred to as cerebral aneurysm.Arteriae cerebri
Knurl easily induces subarachnoid hemorrhage in rupture, so as to cause sufferer apoplexy；Even, 80% or more patient recurring
Can be dead after cerebral aneurysm rupture.Therefore, the earlier stage occurred as far as possible in cerebral aneurysm carries out embolism or envelope
It is stifled to turn into optimal healing means.
In the method for embolism cerebral aneurysm, typically the aneurysm formed is blocked using surgical operation,
Including clamping aneurysm neck for the cutting of aneurysm mother's artery, ligation and using aneurysm clip, so as to block blood to dynamic
The impact of arteries and veins knurl.But this method is time-consuming longer and is likely to cause aneurysmal breakage.In recent years, with blood vessel image
Development, using intervention operation method, by various embolism materials being delivered in cerebral aneurysm to block, embolism artery
Knurl instead of traditional surgical operation gradually.However, thrombosis rate using the method for noble metal turn is relatively low, easy shape
Cause cerebrum block etc. into large-scale thrombus.And as a rule, an aneurysm filling operation, averagely needs 4-5
Turn.Turn expense is tens of thousands of tens of thousands of to ten.It is undoubtedly a huge burden for patient and patient family.
Have been disclosed for multiple intra-arterial knurl choke material at present, be broadly divided into solid embolism materials such as noble metal turn and
The class of liquid embolic material two.Liquid embolic material can be directly injected into aneurysm knurl intracavitary, adapt to the dynamic of different shape and size
Arteries and veins knurl chamber, make not staying any space between knurl wall and embolism materials, so as to reach permanent occlusion.Such as the Onyx of EV3 Company
HD500 is exactly a liquid embolizing agent specifically for aneurysm filling.Onyx glue composition is very simple, and it is gathered by polyvinyl alcohol
Ethylene copolymer EVOH, dimethyl sulfoxide (DMSO) DMSO solvents and the Ta powder used Ta compositions of micron.Wherein Onyx18 and Onyx34 move in brain
It is commonly used in the embolism of venous malformation (AVM).Because it allows doctor to inject for a long time, with more preferable dispersivity and more
High thrombosis rate, autography, and there is the characteristics of non-adhering.But Onyx HD500 are applied to the liquid of intracranial aneurysm filling
Body embolism materials are cumbersome but because it is using complexity.Need to protect the knurl mouth of parent artery with sacculus, prevent liquid
Body glue is gone to outside aneurysm.And want multiple full and contraction operation.Nonetheless still it is possible to there can be liquid glue race
Go out aneurysmal dangerous generation.So this product has stopped selling substantially.
Micro-fluidic (Microfluidics) is referred to using microchannel (size arrives hundreds of microns to be tens of) processing or manipulated
Science and Technology involved by the system of minute fluid (volume for nanoliter arrive A Sheng), it is one and is related to chemistry, fluid physics, micro-
Electronics, new material, the emerging cross discipline of biology and biomedical engineering.One of micro-fluidic key character is minute yardstick ring
There is unique fluid properties, such as laminar flow and drop under border.It is micro-fluidic to realize one by these unique fluid phenomenons
Serial conventional method is difficult to the micro Process completed and microoperation.Main fluid phenomenon has drop and laminar flow.
1, the drop of microflow control technique
When the immiscible liquid of two-phase (You Heshui) flows in microfluidic channel, in liquid/liquid interface tension force and shearing
In the presence of power, wherein one phase flow is known from experience to form highly homogeneous cutout, i.e. drop.In method prepared by emulsion, if
It is top-down to say the method based on stirring, then it is micro-fluidic, it is bottom-to-top method.It is micro-fluidic can be with very high
Flux prepare high degree of monodispersity drop emulsion.Common MCA is T-shaped and ψ types.In some cases, contain
The aqueous phase liquid of different high molecular polymers can also form immiscible drop in microfluidic channel.Based on this method, China
Liu Shanshan of middle University of Science and Technology et al. is prepared for PCI autography blood vessel embolism polymer microballoon.They are with sodium alginate
The aqueous solution is dispersed phase, to contain generated in-situ CaCl2The atoleine of nanoparticle is continuous phase, micro-fluidic based on drop type
Technology combination precrosslink method, size tunable and single dispersing, the calcium alginate gel bead of good sphericity is made.Method can pass through
Change micro fluidic device construction size and the velocity ratio of continuous phase and dispersed phase, regulation and control gel micro-ball size is at 40 μm~700 μm
Between.Resulting microspherulite diameter distribution is homogeneous, and has good X-ray developability.
2, the laminar flow of microflow control technique
Laminar flow is corresponding with turbulent flow, refers to the laminar flow of fluid, and its streamline is parallel to each other with tube wall.In viscous force much
More than inertia force, or when Reynolds number (Reynold number) is less than 3000, laminar flow just occurs.When the stream of a few phase different colours
Body from different entrances enter same microchannel when, even if they dissolve each other, can also form well-bedded multiphase PARALLEL FLOW.
It is regular using this geometry of laminar flow, it is possible to achieve the ordered arrangement of material, chemical environment and cell in microchannel.
The content of the invention
The present invention has following technical essential and key element：
This microtubular for being used for neural interventional treatment is two-piece design.As shown in figure 3, its proximal segment has annula
Structure, there are exocoel 3-1 and inner chamber 3-2.And be single cavity body structure in distal ports, " turn (3-3) can this section again for polymer
Solidification, or spiralization.
Form visible " polymer springs circle " the inner chamber solution of X developments and be necessary for liquid embolic with developability itself
Agent.
Exocoel solution is the aqueous solution for having some shear viscosities, exocoel solution and inner chamber solution in distal end single-chamber section forming layer
Fluid is flowed, and the liquid embolizing agent of inner chamber solution is gradually solidified.
Proximal segment has annula structure, and rule of thumb, it is square structure to be preferably designed for exocoel (1-1 and 4-1),
It is preferred that inner chamber (1-2 and 4-2) is circular configuration.As shown in Figure 1 and Figure 4.
Microflow control technique, liquid embolizing agent technology and microtubular technology are combined by the present invention, and preferred liquid suppository is
Can developer liquids suppository, more preferably non-sticky can developer liquids suppository.Thus achieve liquid embolizing agent direct transformation
Develop visible " polymer springs circle " for X.Closely packed filling can be realized for intracranial aneurysm by being somebody's turn to do " polymer springs circle ".
The injection of inner chamber solution can be stopped at any time during filling, retain the injection flow velocity of exocoel solution, realize similar
Noble metal turn frees process.Simple to operate, process control is good.
Brief description of the drawings
Below in conjunction with drawings and Examples, the invention will be further described, in accompanying drawing：
Fig. 1, microtubular cross-sectional；
Fig. 2：Micro-fluidic vertical section photo；
Fig. 3：Microtubular vertical section and " polymer springs circle " form schematic diagram；
Fig. 4 microfluidic controls are for coiling-type polymer " turn " schematic diagram；
Fig. 5：Polymer " turn " microphotograph.
Embodiment
Below in conjunction with the embodiment of specific embodiment
The above of the present invention is described in further detail.
The present invention is based on micro-fluidic laminar fluid form, and liquid embolizing agent technology is combined in it.Thus, may be used
To be formed " the polymer springs circle " of a kind of injectable.We are for microtubular structure, according to micro-fluidic forming layer manifold state institute
The feature needed is designed, and the microtubular of the design has two-way feed pathway (exocoel inner chamber double cavity structure)：Central circular passage
For liquid embolizing agent path, peripheral square duct is the aqueous solution channel (referring to Fig. 2) for having viscosity.The cross-sectional view of structure is such as
Shown in Fig. 1.
Can developer liquids suppository can by polyvinyl alcohol polyethylene and ethylene copolymers (EVOH), dimethyl sulfoxide (DMSO) (DMSO) solvent and
The Ta powder used composition of micron.Tantalum powder is developer or other noble metal micron powders.Polymer EVOH is dissolved in DMSO
In, but it is not dissolved in water.So when EVOH DMSO solution runs into water or blood, polymer will be from DMSO solvents
In be precipitated out.Ta powder can be embedded in the colloidal condensate of its formation by polymer EVOH precipitation processes.Because it has embedded Ta
Powder, so it can develop under X-ray.Liquid embolizing agent will gradually be cured as polymer in by the microtubular
Rice noodles shape " filling turn ".And we can allow it to be come out in microtubular by the length for the laminar flow section for adjusting microtubular
Fully solidify when in into human body artery knurl.After aneurysm filling is complete, doctor need to only stop bore passages solution
Injection, and retain the solution injection of exocoel passage.This process is visual to free process for turn.By this process,
Doctor is to clog multiple noble metal turns before " the polymer springs circle " that can use a liquid embolizing agent to be formed reaches
Effect.And filling is finer and close, process is more reliable.And the financial burden of patient can be largely reduced, because " polymer
The cost of turn " is far below noble metal turn.
In addition, this microtubular for being used for neural interventional treatment is two-piece design.As shown in figure 3, its proximal segment has together
Axle double cavity structure, there are exocoel 3-1 and inner chamber 3-2.And be single cavity body structure in distal ports, " turn (3-3) can be again for polymer
This section solidifies, or spiralization.
Below to enumerating example, to the further specific descriptions of the present invention.1, experimental raw and reagent
Polyvinylpyrrolidone (Mn=500,0g/mol, analyzes pure, Chemical Reagent Co., Ltd., Sinopharm Group)；Diformazan is sub-
Sulfone (DMSO, analyzes pure, Chemical Reagent Co., Ltd., Sinopharm Group)；Polyethylene glycol (PEG400, Mn=400g/mol, analysis is pure,
Chemical Reagent Co., Ltd., Sinopharm Group)；Ta powder (micron-nanometer level) (Ningxia east tantalum industry)；EVOH polymer (Taiwan Changchun
Company)
2, micro fluidic device is built
Single emulsion capillary micro fluidic device is built：Two pipes are inserted into square tube, Cheng Yi from the both sides of square tube respectively
It is arranged in a straight line, and the pipe after assembling is fixed on slide.As shown in figure 4, the pipe in left side is as interior phase passage, square tube
Left side is as foreign minister's passage, and the pipe on right side is as collecting region one section (4-3).The internal diameter and external diameter of pipe are 600 μm respectively
And 1.0mm, the internal diameter of square tube is 1.0mm.Diameter is truncated to 30 μm by the end of inlet tube after drawing pin device to burn carefully, then by burning pin device
Left and right.The end that one section of collecting region, which connects bigger two sections of the collecting region (4-4) of an internal diameter, (has the polytetrafluoroethyl-ne of different inner diameters
The square tube that alkene pipe either internal diameter is 1mm).
As shown in figure 4, the mixed solution of EVOH/DMSO/Ta powder and the PEG aqueous solution are mixed as interior phase and outside
Liquid.Two-phase is injected in the internal and external channel of micro fluidic device by syringe pump respectively, and two parallel streams are formed in one section of collecting region
Body.Then two parallel fluids enter broader two sections of a collecting region, and screw type can be spontaneously generated in two sections of collecting region
Fiber.Wherein, dj is the diameter of initial fluid in figure；Df is the diameter for the solid fiber being collected into；D1 is the internal diameter of capillary；
D2 is the internal diameter of two sections of collecting region；λ is the wavelength of helically oriented fiber, and l is between one section of end of import pipe end and collecting region
Distance.In this process, after dispersed phase enters one section of collecting region, the DMSO in fluid starts to move to continuous phase liquid PEG phases
Move.With DMSO migration, the viscosity of internal phase fluid increases, and starts to shrink at.This can cause the accumulation of elastic energy and stress,
It can only can be discharged by folding.Meanwhile passage broadens and causes interior foreign minister to produce speed difference, this can be produced to internal phase fluid
Viscous drag, so as to cause curling.In addition, as the DMSO in the mixed solution of EVOH/DMSO/Ta powder is quickly to liquid PEG
Spread in phase, interior phase liquid can progressively solidify, and the shape of spiral will be maintained after solidification.Straight fluid/fiber is changed into screw type
Fiber is to be broadened from the water of interior phase to foreign minister's migration and passage caused by the synergy of (collecting region one section to collecting region two sections).
It should be noted that this and be based on two-phase aqueous systems before, microfluidic control is for the report of microballoon or microfibre difference.At these
In report, they be PEG the aqueous solution and Quick cross-linking in situ realize solidification.
Concentration by simply adjusting the flow velocity of interior foreign minister, l values and EVOH/DMSO solution etc., can be made not similar shape
The fiber of looks, including screw type, the fiber of wavy and unordered curling.For all these fibers, df/djControl 0.5
Left and right (table 1).Illustrate in this preparation process, due to the diffusion of water, the diameter of liquid embolizing agent phase reduces~50%.Cause
This, we can adjust the initial diameter of fluid simply by the flow velocity of foreign minister in change, so as to control final fiber
Diameter (table 1).
Embodiment 1-4 is as shown in table 1：
Influence of foreign minister's flow velocity to dj, df and df/dj in table 1
Embodiment 5, Qin=200 μ L/h, Qout=5mL/h, d1=600 μm, EVOH/DMSO=6wt%), l=3cm dresses
Put.
Embodiment 6, Qin=200 μ L/h, Qout=5mL/h, d1=600 μm, EVOH/DMSO=6wt%), l=6cm dresses
Put.
Embodiment 7, Qin=200 μ L/h, Qout=5mL/h, d1=600 μm, EVOH/DMSO=6wt%), l=9cm dresses
Put.
Embodiment 8, Qin=200 μ L/h, Qout=5mL/h, d1=600 μm, EVOH/DMSO=8wt%), l=9cm dresses
Put.
Embodiment 9, Qin=200 μ L/h, Qout=5mL/h, d1=600 μm, EVOH/DMSO=10wt%), l=9cm dresses
Put.
By above example, micro-fluidic resulting polymer " turn " is as shown in Figure 5.1-9 examples correspond to 5-a respectively
To 5-i.
Claims (10)
1. a kind of microtubular for ganglioside GM_3 operation, it is characterised in that the microtubular is including at least in being coaxially disposed
Heart passage and peripheral channel, central passage for can developer liquids suppository path, peripheral channel is the aqueous solution channel for having viscosity,
Can spiralization and solidification of the developer liquids suppository in microtubular with realization.
2. microtubular according to claim 1, it is characterised in that：The microtubular divides two-piece design, and proximal segment is formed
The central passage and peripheral channel, and the peripheral channel is square structure, central passage is circular configuration；And distal ports are
Single lumen catheter structure.
3. microtubular according to claim 1, it is characterised in that：It is described can developer liquids suppository comprise at least water it is insoluble
The polymer of solution, can solvent corresponding to developer liquids suppository and micronized three compositions of noble metal powder.
4. microtubular according to claim 3, it is characterised in that：Also contain polyethylene-polyethylene in the liquid embolizing agent
The copolymer EVOH of alcohol repeat unit.
5. microtubular according to claim 3, it is characterised in that：The solvent is 1-METHYLPYRROLIDONE, or N-
The mixed solvent of methyl pyrrolidone and DMSO, or the mixed solvent of 1-METHYLPYRROLIDONE, DMSO and absolute ethyl alcohol, or
Person is the mixed solvent of 1-METHYLPYRROLIDONE and absolute ethyl alcohol.
6. microtubular according to claim 3, it is characterised in that：It is described can developer liquids suppository further comprising development
Agent, the developer are micronized ta powders, or micronized platinum powder, or micronized platinum-tungsten alloys powder
End.
7. microtubular according to claim 1, it is characterised in that：The aqueous solution is polyethylene glycol PEG either polyethylene
The base pyrrolidones PVP aqueous solution.
8. a kind of method that microtubular using as described in any one of claim 1~7 carries out fluid intervention, its feature exist
In, including step：
Can developer liquids suppository from central passage injection；
The aqueous solution of specific shear viscosity is injected with from peripheral channel；
Control two kinds of solution of A, B velocity ratio, realize pair can developer liquids suppository cavity diameter and helical pitch regulation
Control.
9. the method for fluid intervention according to claim 8, further comprises step：
In fluid intervention procedure, stop the injection of B solution as needed, and retain the injection flow velocity of solution A, realize similar expensive
Metal elastic spring coil frees process.
10. the method for fluid intervention according to claim 8, further comprises step：
Liquid embolizing agent is gradually cured as the rice noodles shape " filling turn " of polymer in by the microtubular；And
Adjust the length of the laminar flow section of microtubular so that liquid embolizing agent fully solidifies when microtubular comes out.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711197379.XA CN107811669B (en) | 2017-11-25 | 2017-11-25 | Microtubular for ganglioside GM_3 operation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711197379.XA CN107811669B (en) | 2017-11-25 | 2017-11-25 | Microtubular for ganglioside GM_3 operation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107811669A true CN107811669A (en) | 2018-03-20 |
| CN107811669B CN107811669B (en) | 2019-07-19 |
Family
ID=61609923
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711197379.XA Active CN107811669B (en) | 2017-11-25 | 2017-11-25 | Microtubular for ganglioside GM_3 operation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107811669B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109675123A (en) * | 2019-01-30 | 2019-04-26 | 温州市人民医院 | A kind of alimentary canal sharppointed article taking-up external member based on protective film and package spray technology |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040158185A1 (en) * | 1998-12-01 | 2004-08-12 | Moran Christopher J. | Embolization device |
| US20100249774A1 (en) * | 2003-06-05 | 2010-09-30 | Dfine, Inc. | Polymer composites for biomedical applications and methods of making |
| CN104829851A (en) * | 2015-04-24 | 2015-08-12 | 山东省科学院能源研究所 | Preparation method of mono-dispersed gelatin embolic microsphere with precisely-controlled particle size |
| CN104829850A (en) * | 2015-04-14 | 2015-08-12 | 华中科技大学 | Spherical calcium alginate gel micro-particle preparation method |
| CN104857576A (en) * | 2015-04-24 | 2015-08-26 | 山东省科学院能源研究所 | Method for preparation of polyvinyl alcohol embolism microball by synchronous solidification |
| CN104906049A (en) * | 2015-06-10 | 2015-09-16 | 山东省科学院能源研究所 | Sodium alginate microsphere vascular embolization agent and preparation method thereof |
| US20160296723A1 (en) * | 2015-04-07 | 2016-10-13 | Rany Busold | Mixing catheter for two-part system |
-
2017
- 2017-11-25 CN CN201711197379.XA patent/CN107811669B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040158185A1 (en) * | 1998-12-01 | 2004-08-12 | Moran Christopher J. | Embolization device |
| US20100249774A1 (en) * | 2003-06-05 | 2010-09-30 | Dfine, Inc. | Polymer composites for biomedical applications and methods of making |
| US20160296723A1 (en) * | 2015-04-07 | 2016-10-13 | Rany Busold | Mixing catheter for two-part system |
| CN104829850A (en) * | 2015-04-14 | 2015-08-12 | 华中科技大学 | Spherical calcium alginate gel micro-particle preparation method |
| CN104829851A (en) * | 2015-04-24 | 2015-08-12 | 山东省科学院能源研究所 | Preparation method of mono-dispersed gelatin embolic microsphere with precisely-controlled particle size |
| CN104857576A (en) * | 2015-04-24 | 2015-08-26 | 山东省科学院能源研究所 | Method for preparation of polyvinyl alcohol embolism microball by synchronous solidification |
| CN104906049A (en) * | 2015-06-10 | 2015-09-16 | 山东省科学院能源研究所 | Sodium alginate microsphere vascular embolization agent and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 刘珊珊: "《介入栓塞用自显影海藻酸盐凝胶微球的可控制备及性能》", 31 May 2017 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109675123A (en) * | 2019-01-30 | 2019-04-26 | 温州市人民医院 | A kind of alimentary canal sharppointed article taking-up external member based on protective film and package spray technology |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107811669B (en) | 2019-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | Microfluidic-assisted fabrication of carriers for controlled drug delivery | |
| KR101902475B1 (en) | Optimization of the Designing of Apparatus and Processes for Mass Production of Monodisperse Biodegradable Polymer-based Microspheres and Biodegradable Polymer-based Drug Delivery Systems | |
| Hu et al. | Microfluidic fabrication of shape-tunable alginate microgels: Effect of size and impact velocity | |
| Liu et al. | Smart thermo-triggered squirting capsules for nanoparticle delivery | |
| Ekanem et al. | Structured biodegradable polymeric microparticles for drug delivery produced using flow focusing glass microfluidic devices | |
| CN104829850B (en) | A kind of preparation method of spherical calcium alginate gel particulate | |
| Kashani et al. | Microfluidics for core–shell drug carrier particles–a review | |
| CN104857576B (en) | Method for preparation of polyvinyl alcohol embolism microball by synchronous solidification | |
| CN106040117B (en) | The method that monodispersity calcium alginate microsphere is prepared based on emulsion liquid membrane mass transfer | |
| Chen et al. | Continuous synthesis of polymer-coated drug particles by porous hollow fiber membrane-based antisolvent crystallization | |
| JP2017024005A (en) | Multi-phase emulsion and formation method of multi-phase emulsion | |
| Wang et al. | Microfluidic preparation of multicompartment microcapsules for isolated co-encapsulation and controlled release of diverse components | |
| Zhu et al. | Rapid production of single-and multi-compartment polymeric microcapsules in a facile 3D microfluidic process for magnetic separation and synergistic delivery | |
| CN107811669B (en) | Microtubular for ganglioside GM_3 operation | |
| US20220160930A1 (en) | Preparation method for non-spherical hydrogel microparticle embolic agent | |
| Carugo et al. | A microfluidic device for the characterisation of embolisation with polyvinyl alcohol beads through biomimetic bifurcations | |
| Xu et al. | A region-selective modified capillary microfluidic device for fabricating water–oil Janus droplets and hydrophilic–hydrophobic anisotropic microparticles | |
| CN108686258A (en) | Interpenetrating networks embolism microball and preparation method thereof | |
| Xian-Wei et al. | Preparation of poly (vinyl alcohol) microspheres based on droplet microfluidic technology | |
| Luo et al. | Novel synthesis of PVA/GA hydrogel microspheres based on microfluidic technology | |
| CN207680583U (en) | A kind of micro-fluidic preparation facilities of polymer micro-emulsion | |
| Wu et al. | Peanut-inspired anisotropic microparticles from microfluidics | |
| Seo et al. | Microfluidic synthesis of thermo-responsive poly (N-isopropylacrylamide)–poly (ethylene glycol) diacrylate microhydrogels as chemo-embolic microspheres | |
| JP7267442B2 (en) | Method for forming slug flow, method for producing organic compounds, method for producing particles, and method for extraction | |
| AU2014225283A1 (en) | An apparatus for producing nano-bodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20191220 Address after: 310012 room 380, building 3, No. 16, Zhuantang science and technology economic block, Xihu District, Hangzhou City, Zhejiang Province Patentee after: HANGZHOU HUAWEI MEDICAL TECHNOLOGY Co.,Ltd. Address before: O 03-04 Changhong technology building 18 unit 9 floor No. 518000 Guangdong city of Shenzhen province Nanshan District Guangdong science and Technology Street twelve South Road Patentee before: HUAWEI (SHENZHEN) MEDICAL EQUIPMENT Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240124 Address after: No. 1, Building 6, No. 19 Fanggui Middle Road, Quzhou City, Zhejiang Province, 324000 Patentee after: Zhejiang Meitingnuo Medical Technology Co.,Ltd. Country or region after: China Address before: Room 380, Building 3, No. 16, Zhuantang Science and Technology Economic Block, Xihu District, Hangzhou City, Zhejiang Province, 310012 Patentee before: HANGZHOU HUAWEI MEDICAL TECHNOLOGY Co.,Ltd. Country or region before: China |
|
| TR01 | Transfer of patent right |